Adaptimmune tech chief to depart next month; shares down 12%

|About: Adaptimmune Therapeuti... (ADAP)|By:, SA News Editor

Adaptimmune Therapeutics (ADAP -12%) is down on almost double normal volume in apparent response to the announced departure of Chief Technology Officer Gwen Binder, Ph.D. at the end of next month.

She was the first U.S. employee in 2011 and was instrumental in the advancement of its cell therapies.

Subscribe for full text news in your inbox